# Cacao Flavanol Exercise Performance Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/cacao-flavanol-exercise-performance-meta-analysis-evidence-review
Category: evidence-review
Summary: Cacao Flavanol Exercise Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this firs
Last reviewed: 2026-08-07
Reviewed by: Migaku Evidence Review
# Cacao Flavanol Exercise Performance Meta-analysis: What the Evidence Says

## Quick Answer

Cacao Flavanol Exercise Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Response of VO 2max to dark chocolate consumption in healthy subjects: A systematic review and meta‐analysis of randomized controlled trials | systematic review | 1 | 2025-02-25 | 10.14814/phy2.70256 |
| Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors | narrative review | 3 | 2026-02-14 | 10.3390/nu18040636 |

## What The Sources Report

- Studies have indicated that higher levels of aerobic capacity are associated with improved athletic performance and a reduced risk of cardiovascular diseases, as well as lower mortality rates in non-athletes (McKendry et al., ). [Mehdipour Aref (2025); evidence level 1]
- Overall, enhancing aerobic capacity can contribute to improved quality of life and better public health (Blair et al., ; Kodama et al., ; Lee et al., ). [Mehdipour Aref (2025); evidence level 1]
- MetS is a multifactorial condition, with its primary indicators including obesity, hypertension, dyslipidemia, insulin resistance, and hyperglycemia; i.e., a patient who possesses at least 3 of the following parameters is designated with MetS: glucose intolerance, increased levels of triglycerides, augmented waist circumference, low levels of high-density lipoprotein cholesterol (HDL-c), and hypertension. [Tomaru Júlia Mayumi (2026); evidence level 3]
- It is possible to develop a close relationship with MetS, metabolic dysfunction-associated steatotic liver disease (MASLD), and CVD. [Tomaru Júlia Mayumi (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For cacao flavanol exercise performance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Mehdipour Aref (2025). Response of VO 2max to dark chocolate consumption in healthy subjects: A systematic review and meta‐analysis of randomized controlled trials. DOI: 10.14814/phy2.70256. PMCID: PMC11859664. PMID: 40000922. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC11859664/
- Tomaru Júlia Mayumi (2026). Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. DOI: 10.3390/nu18040636. PMCID: PMC12943539. PMID: 41754152. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12943539/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.